An2 Therapeutics Stock Revenue
| ANTX Stock | USD 2.56 0.02 0.79% |
AN2 Therapeutics fundamentals help investors to digest information that contributes to AN2 Therapeutics' financial success or failures. It also enables traders to predict the movement of AN2 Stock. The fundamental analysis module provides a way to measure AN2 Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AN2 Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 0.00 | 0.00 |
AN2 | Revenue |
AN2 Therapeutics Company Revenue Analysis
AN2 Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of AN2
Projected quarterly revenue analysis of AN2 Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of AN2 Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in AN2 Therapeutics' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, AN2 Therapeutics reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
AN2 Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AN2 Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AN2 Therapeutics could also be used in its relative valuation, which is a method of valuing AN2 Therapeutics by comparing valuation metrics of similar companies.AN2 Therapeutics is currently under evaluation in revenue category among related companies.
AN2 Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in AN2 Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of AN2 Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing AN2 Therapeutics' value.| Shares | Blackrock Inc | 2023-12-31 | 305.8 K | T. Rowe Price Associates, Inc. | 2023-12-31 | 187.4 K | Geode Capital Management, Llc | 2023-12-31 | 178.6 K | Citigroup Inc | 2023-12-31 | 160.5 K | Amvescap Plc. | 2023-12-31 | 157.9 K | Longwood Capital Partners Llc | 2023-12-31 | 132 K | Susquehanna International Group, Llp | 2023-12-31 | 99.4 K | Qube Research & Technologies | 2023-12-31 | 72.2 K | Jane Street Group, Llc | 2023-12-31 | 59.4 K | Ra Capital Management, Llc | 2023-12-31 | 5.6 M | Tcg Crossover Management, Llc | 2023-12-31 | 2.7 M |
AN2 Fundamentals
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | (31.68 M) | ||||
| Shares Outstanding | 29.83 M | ||||
| Shares Owned By Insiders | 25.88 % | ||||
| Shares Owned By Institutions | 69.89 % | ||||
| Number Of Shares Shorted | 460.51 K | ||||
| Price To Earning | 3.96 X | ||||
| Price To Book | 0.65 X | ||||
| EBITDA | (69.64 M) | ||||
| Net Income | (64.73 M) | ||||
| Cash And Equivalents | 113.39 M | ||||
| Cash Per Share | 5.84 X | ||||
| Total Debt | 53 K | ||||
| Current Ratio | 28.17 X | ||||
| Book Value Per Share | 4.19 X | ||||
| Cash Flow From Operations | (53.29 M) | ||||
| Short Ratio | 1.07 X | ||||
| Earnings Per Share | (2.74) X | ||||
| Target Price | 16.0 | ||||
| Number Of Employees | 41 | ||||
| Beta | -0.24 | ||||
| Market Capitalization | 75.77 M | ||||
| Total Asset | 138.74 M | ||||
| Retained Earnings | (154.46 M) | ||||
| Working Capital | 96.46 M | ||||
| Net Asset | 138.74 M |
About AN2 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AN2 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AN2 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AN2 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with AN2 Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AN2 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AN2 Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to AN2 Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AN2 Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AN2 Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AN2 Therapeutics to buy it.
The correlation of AN2 Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AN2 Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AN2 Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AN2 Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out AN2 Therapeutics Piotroski F Score and AN2 Therapeutics Altman Z Score analysis. For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for AN2 Stock analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is AN2 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AN2 Therapeutics. If investors know AN2 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AN2 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.74) | Return On Assets (0.36) | Return On Equity (0.59) |
The market value of AN2 Therapeutics is measured differently than its book value, which is the value of AN2 that is recorded on the company's balance sheet. Investors also form their own opinion of AN2 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is AN2 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AN2 Therapeutics' market value can be influenced by many factors that don't directly affect AN2 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AN2 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AN2 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AN2 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.